According to Canadian advocates, over 130 healthcare professionals are about to be denied compassionate access to psilocybin mushrooms for training purposes via Section 56 exemptions, following a decision by federal health authorities.
“It would appear that Health Canada has decided [to deny access] because a clinical trial has been approved to test the safety of psilocybin on subjects in training,” says Spencer Hawkswell, CEO of TheraPsil, a British Columbia-based non-profit patients rights advocacy group.
Share this post
